Professor Penelope D Ottewell

All publications

Journal articles

• Morita M, Arshad F, Quayle LA, George CN, Lefley DV, Kalajzic I, Balsubramanian M, Cebe T, Reilly G, Bishop NJ & Ottewell PD (2024) Losartan alters osteoblast differentiation and increases bone mass through inhibition of TGFB signalling in vitro and in an OIM mouse model. Bone Reports, 22, 101795-101795.
• Zhou J & Ottewell PD (2024) The role of IL-1B in breast cancer bone metastasis. Journal of Bone Oncology, 46, 100608-100608.
• Kwan A, Stark K, Allen R, Ottewell P & Muthana M (2024) An Overview of the Bench to Bedside Models of Breast Cancer in the Era of Cancer Immunotherapy. Medical Research Archives, 12(6).
• Zhou J, Tulotta C & Ottewell PD (2022) IL-1β in breast cancer bone metastasis. Expert Reviews in Molecular Medicine, 24.
• Canuas-Landero VG, George CN, Lefley DV, Corness H, Muthana M, Wilson C & Ottewell PD (2021) Oestradiol contributes to differential antitumour effects of adjuvant zoledronic acid observed between pre- and post-menopausal women. Frontiers in Endocrinology, 12.
• Tulotta C, Lefley DV, Moore CK, Amariutei AE, Spicer-Hadlington AR, Quayle LA, Hughes RO, Ahmed K, Cookson V, Evans CA , Vadakekolathu J et al (2021) IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer. npj Breast Cancer, 7(1).
• George C, Lefley D, Canuas-Landero V, Tulotta C, Corness H, Wilson C, Muthana M & Ottewell P (2021) Differential effects of zoledronic acid and oestrogen on anti-cancer immunity. Bone Reports, 14, 101024.
• Canuas-Landero V, George C, Lefley D, Wilson C & Ottewell P (2021) Interactions between oestradiol and zoledronic acid in the bone microenvironment; physiological changes altering metastatic potential of breast cancer cells in pre- and post-menopausal women. Bone Reports, 14, 100899.
• Ottewell PD & Lawson MA (2021) Advances in murine models of breast cancer bone disease. Journal of Cancer Metastasis and Treatment, 7. View this article in WRRO
• Bishop RT, Marino S, Carrasco G, Li B, Allen RJ, Sparatore A, Ottewell PD, Mollat P, Sims AH, Capulli M , Wang N et al (2020) Combined administration of a small-molecule inhibitor of TRAF6 and Docetaxel reduces breast cancer skeletal metastasis and osteolysis. Cancer Letters, 488, 27-39.
• George CN, Canuas-Landero V, Theodoulou E, Muthana M, Wilson C & Ottewell P (2020) Oestrogen and zoledronic acid driven changes to the bone and immune environments: Potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions. Journal of Bone Oncology, 25, 100317-100317.
• Ran R, Harrison H, Syamimi Ariffin N, Ayub R, Pegg HJ, Deng W, Mastro A, Ottewell PD, Mason SM, Blyth K , Holen I et al (2020) A role for CBFβ in maintaining the metastatic phenotype of breast cancer cells. Oncogene. View this article in WRRO
• Lefley D, Howard F, Arshad F, Bradbury S, Brown H, Tulotta C, Eyre R, Alférez D, Wilkinson JM, Holen I , Clarke RB et al (2019) Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts. Breast Cancer Research, 21(1). View this article in WRRO
• Eyre R, Alférez DG, Santiago-Gómez A, Spence K, McConnell JC, Hart C, Simões BM, Lefley D, Tulotta C, Storer J , Gurney A et al (2019) Microenvironmental IL1β promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling. Nature Communications, 10(1). View this article in WRRO
• Ottewell P & Wilson C (2019) Bone-targeted agents in breast cancer : do we now have all the answers?. Breast Cancer: Basic and Clinical Research, 13. View this article in WRRO
• Allocca G, Hughes R, Wang N, Brown HK, Ottewell PD, Brown NJ & Holen I (2019) The bone metastasis niche in breast cancer–potential overlap with the haematopoietic stem cell niche in vivo. Journal of Bone Oncology, 17. View this article in WRRO
• Bishop RT, Marino S, de Ridder D, Allen RJ, Lefley DV, Sims AH, Wang N, Ottewell PD & Idris AI (2019) Pharmacological inhibition of the IKKε/TBK-1 axis potentiates the anti-tumour and anti-metastatic effects of Docetaxel in mouse models of breast cancer. Cancer Letters, 450, 76-87. View this article in WRRO
• Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter-Howard F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury S et al (2019) Endogenous production of IL-1B by breast cancer cells drives metastasis and colonisation of the bone microenvironment.. Clinical Cancer Research, 25(9), 2769-2782. View this article in WRRO
• Al-Sahaf S, Hunter KD, Bolt R, Ottewell PD & Murdoch C (2019) The IL-1/IL-1R axis induces greater fibroblast-derived chemokine release in human papillomavirus-negative compared to positive oropharyngeal cancer. International Journal of Cancer, 144(2), 334-344. View this article in WRRO
• Quayle LA, Ottewell PD & Holen I (2018) Chemotherapy resistance and stemness in mitotically quiescent human breast cancer cells identified by fluorescent dye retention. Clinical and Experimental Metastasis. View this article in WRRO
• Brown HK, Allocca G, Ottewell PD, Wang N, Brown NJ, Croucher PI, Eaton CL & Holen I (2018) Parathyroid Hormone (PTH) Increases Skeletal Tumour Growth and Alters Tumour Distribution in an In Vivo Model of Breast Cancer.. International Journal of Molecular Sciences, 19(10). View this article in WRRO
• Tulotta C & Ottewell PD (2018) The role of IL-1B in breast cancer bone metastasis. Endocrine-Related Cancer, 25(7), R421-R434. View this article in WRRO
• Holen I, Whitworth J, Nutter F, Evans A, Brown HK, Lefley DV, Barbaric I, Jones M & Ottewell PD (2017) Erratum to: Loss of plakoglobin promotes cell-cell contact, increased invasion and breast cancer cell dissemination in vivo.. Breast Cancer Research, 19.
• Holen I, Lefley DV, Francis SE, Rennicks S, Bradbury S, Coleman RE & Ottewell P (2016) IL-1 drives breast cancer growth and bone metastasis in vivo.. Oncotarget, 7, 75571-75584. View this article in WRRO
• Ottewell PD (2016) The role of osteoblasts in bone metastasis. Journal of Bone Oncology, 5(3), 124-127. View this article in WRRO
• Ottewell P, Brown H, Allocca G, Haider MT, Brown N & Holen I (2016) The bone microenvironment as a master regulator of tumour cell dormancy in breast cancer - evidence from novel in vivo models. European Journal of Cancer, 61, S74-S75.
• Wright LE, Ottewell PD, Rucci N, Peyruchaud O, Pagnotti GM, Chiechi A, Buijs JT & Sterling JA (2016) Murine models of breast cancer bone metastasis. BoneKEy Reports, 5, 804-804. View this article in WRRO
• Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Wood SL, Ottewell PD, Marshall H, Banks RE , Selby PJ et al (2016) CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment. Journal of the National Cancer Institute, 108(4). View this article in WRRO
• Holen I, Walker M, Nutter F, Fowles A, Evans CA, Eaton CL & Ottewell PD (2016) Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo. Clinical & Experimental Metastasis, 33(3), 211-224. View this article in WRRO
• Wang N, Reeves KJ, Brown HK, Fowles ACM, Docherty FE, Ottewell PD, Croucher PI, Holen I & Eaton CL (2015) The frequency of osteolytic bone metastasis is determined by conditions of the soil, not the number of seeds; evidence from in vivo models of breast and prostate cancer. Journal of Experimental and Clinical Cancer Research, 34(1), 124-124. View this article in WRRO
• Ottewell PD, Wang N, Brown HK, Fowles CA, Croucher PI, Eaton CL & Holen I (2015) OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone. International Journal of Cancer, 137(4), 968-977. View this article in WRRO
• Holen I, Nutter F, Wilkinson JM, Evans CA, Avgoustou P & Ottewell PD (2015) Human breast cancer bone metastasis in vitro and in vivo: a novel 3D model system for studies of tumour cell-bone cell interactions. Clinical & Experimental Metastasis, 32(7), 689-702. View this article in WRRO
• Wang N, Docherty F, Brown HK, Reeves K, Fowles A, Lawson M, Ottewell PD, Holen I, Croucher PI & Eaton CL (2015) Mitotic quiescence, but not unique “stemness,” marks the phenotype of bone metastasis-initiating cells in prostate cancer. The FASEB Journal, 29(8), 3141-3150. View this article in WRRO
• Quayle L, Ottewell P & Holen I (2015) Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer. Current Cancer Drug Targets, 15(6), 469-480.
• Wilson C, Ottewell P, Coleman RE & Holen I (2015) The differential anti-tumour effects of zoledronic acid in breast cancer – evidence for a role of the activin signaling pathway. BMC Cancer, 15(1). View this article in WRRO
• Ottewell PD, O’Donnell L & Holen I (2015) Molecular alterations that drive breast cancer metastasis to bone. BoneKEy Reports, 4. View this article in WRRO
• Wang N, Docherty FE, Brown HK, Reeves KJ, Fowles ACM, Ottewell PD, Dear TN, Holen I, Croucher PI & Eaton CL (2014) Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis: evidence from in vivo models.. J Bone Miner Res, 29(12), 2688-2696. View this article in WRRO
• Ottewell PD, Wang N, Meek J, Fowles CA, Croucher PI, Eaton CL & Holen I (2014) Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocrine Related Cancer, 21(5), 769-781.
• Ottewell PD, Wang N, Brown HK, Reeves KJ, Fowles CA, Croucher PI, Eaton CL & Holen I (2014) Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.. Clin Cancer Res, 20(11), 2922-2932. View this article in WRRO
• David M, Machuca-Gayet I, Kikuta J, Ottewell P, Mima F, Leblanc R, Bonnelye E, Ribeiro J, Holen I, Vales RL , Jurdic P et al (2014) Lysophosphatidic Acid Receptor Type 1 (LPA1) Plays a Functional Role in Osteoclast Differentiation and Bone Resorption Activity. Journal of Biological Chemistry, 289(10), 6551-6564.
• David M, Machuca-Gayet I, Kikuta A, Ottewell PD, Mima F, Leblanc R, Bonnelye E, Ribeiro J, Holen I, Vales RJ , Jurdic P et al (2014) Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity.. Journal of Biological Chemistry, 10(289), 6551-6564.
• Nutter F, Holen I, Brown HK, Cross SS, Evans CA, Walker M, Coleman RE, Westbrook JA, Selby PJ, Brown JE & Ottewell PD (2014) Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line.. Endocr Relat Cancer, 21(2), 327-341.
• Rogers TL, Wind N, Hughes R, Nutter F, Brown HK, Vasiliadou I, Ottewell PD & Holen I (2013) Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models.. Cell Oncol (Dordr), 36(6), 505-514.
• Holen I, Wang N, Reeves KJ, Fowles AM, Croucher PI, Eaton CL & Ottewell PD (2012) Abstract PD07-08: Zoledronic acid specifically inhibits development of bone metastases in the post-menopausal setting – evidence from an in vivo breast cancer model. Poster Discussion Abstracts.
• Brown HK, Ottewell PD, Evans CA, Coleman RE & Holen I (2012) A single administration of combination therapy inhibits breast tumour progress bone and modifies both osteoblasts and osteoclasts. Journal of Bone Oncology, 1(2), 47-56. View this article in WRRO
• Holen I, Whitworth J, Nutter F, Evans A, Brown HK, Lefley DV, Barbaric I, Jones M & Ottewell PD (2012) Loss of plakoglobin promotes decreased cell-cell contact, increased invasion, and breast cancer cell dissemination in vivo.. Breast Cancer Res, 14(3), R86. View this article in WRRO
• Brown HK, Ottewell PD, Evans CA & Holen I (2012) Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo.. Clin Exp Metastasis, 29(8), 927-938.
• Ottewell PD, Brown HK, Jones M, Rogers TL, Cross SS, Brown NJ, Coleman RE & Holen I (2012) Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice.. Breast Cancer Res Treat, 133(2), 523-536.
• Ottewell PD, Whitworth J, Cross SS, Nutter FH & Holen I (2011) P2-01-20: Reduced Plakoglobin Expression Increases the Metastatic Potential of Breast Cancer Cells.. Poster Session Abstracts.
• Ottewell PD (2011) Meeting report from the 10th international conference on cancer-induced bone disease. IBMS BoneKEy, 8(1), 41-45.
• Brown HK, Ottewell PD, Coleman RE & Holen I (2011) The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells.. J Cell Mol Med, 15(3), 501-513. View this article in WRRO
• Syddall SP, Ottewell PD & Holen I (2010) Combined therapies of bone disease with bisphosphonates.. Curr Pharm Des, 16(27), 2988-2997.
• Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE & Holen I (2010) Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model.. Int J Cancer, 126(2), 522-532.
• Ottewell PD (2010) Effects of gastrin and its precursor peptides upon intestinal epithelia..
• Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE & Holen I (2009) Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.. Mol Cancer Ther, 8(10), 2821-2832.
• Ottewell PD, Lefley DV, Coleman RE & Holen I (2009) Evaluation of the molecular mechanisms for the sequence-dependent, synergistic anti-tumour effects of doxorubicin and zoledronic acid in breast cancer.. Poster Session Abstracts.
• Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE & Holen I (2008) Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.. J Natl Cancer Inst, 100(16), 1167-1178.
• Ottewell PD, Deux B, Mönkkönen H, Cross S, Coleman RE, Clezardin P & Holen I (2008) Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.. Clin Cancer Res, 14(14), 4658-4666.
• Mönkkönen H, Ottewell PD, Kuokkanen J, Mönkkönen J, Auriola S & Holen I (2007) Zoledronic acid-induced IPP/ApppI production in vivo.. Life Sci, 81(13), 1066-1070.
• Ottewell PD, Duckworth CA, Varro A, Dimaline R, Wang TC, Watson AJM, Dockray GJ & Pritchard DM (2006) Gastrin increases murine intestinal crypt regeneration following injury.. Gastroenterology, 130(4), 1169-1180.
• Ottewell PD, Coleman RE & Holen I (2006) From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies.. Breast Cancer Res Treat, 96(2), 101-113.
• Keen H, Dekker B, Lyons S, Disley L, Hastings D, Reader A, Ottewell PD, Watson A & Zweit J (2005) Imaging apoptosis in vivo using 124I-annexin V and PET.. Nucl Med Biol, 4(32), 395-402.
• Dekker B, Keen H, Lyons S, Disley L, Hastings D, Reader A, Ottewell PD, Watson A & Zweit M (2005) MBP-annexin V radiolabeled directly with iodine-124 can be used to image apoptosis in vivo using PET.. Nucl Med Biol, 3(32), 241-252.
• Ottewell PD, Varro A, Dockray GJ, Kirton CM, Watson AJM, Wang TC, Dimaline R & Pritchard DM (2005) COOH-terminal 26-amino acid residues of progastrin are sufficient for stimulation of mitosis in murine colonic epithelium in vivo.. Am J Physiol Gastrointest Liver Physiol, 288(3), G541-G549.
• Ottewell PD, Watson AJM, Wang TC, Varro A, Dockray GJ & Pritchard DM (2003) Progastrin stimulates murine colonic epithelial mitosis after DNA damage.. Gastroenterology, 124(5), 1348-1357.
• Pritchard DM, Ottewell PD, Watson AJM, Wang TC & Dockray GJ (2002) Progastrin Stimulates Murine Colonic Epithelial Mitosis after Dna Damage. Clinical Science, 103(s47), 43P-43P.
• Ottewell PD, Watson AJM, Wang TC, Dockray GJ & Pritchard DM (2002) Progastrin stimulates murine colonic epithelial mitosis after DNA damage. GUT, 50, A93-A93.
• Pritchard D, Ottewell PD, Watson AJM, Wang TC & Dockray GJ (2002) Progastrin stimulates murine colonic epithelial mitosis after DNA damage. GASTROENTEROLOGY, 122(4), A684-A684.
• Marshman E, Ottewell PD, Potten CS & Watson AJ (2001) Caspase activation during spontaneous and radiation-induced apoptosis in the murine intestine.. J Pathol, 195(3), 285-292.
• MCMICHAEL D, DAVIES A, MARSHMAN E, OTTEWELL P, JENKINS J & WATSON A (2001) Gene array and knockout mouse analysis of VP-16 induced apoptosis in the murine small intestine. Gastroenterology, 120(5), A660-A660.
• McMichael DP, Davies A, Marshman E, Ottewell PD, Jenkins JR & Watson AJM (2001) Gene array and knockout mouse analysis of VP-16 induced apoptosis in the murine small intestine. GASTROENTEROLOGY, 120(5), A660-A660.
• (2001) Cell Biology/Neoplasia/Coeliac Free Papers. Gut, 48(90001), 60a-64.
• Puppo M, Valluru MK, Croset M, Ceresa D, Iuliani M, Khan A, Wicinski J, Charafe-Jauffret E, Ginestier C, Pantano F , Ottewell PD et al () MiR-662 is associated with metastatic relapse in early-stage breast cancer and promotes metastasis by stimulating cancer cell stemness. British Journal of Cancer.
• Saleh L, Ottewell PD, Brown JE, Wood SL, Brown NJ, Wilson C, Park C, Ali S & Holen I () The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo. Cancers, 15(8), 2211-2211.
• Kwan A, Howard F, Winder N, Atkinson E, Jailani A, Patel PB, Allen R, Ottewell PD, Shaw GC, Conner J , Wilson C et al () Macrophage Delivered HSV1716 Is Active against Triple Negative Breast Cancer. Future Pharmacology, 2(4), 444-459.
• Zhou J, Down JM, George CN, Murphy J, Lefley DV, Tulotta C, Alsharif MA, Leach M & Ottewell PD () Novel Methods of Targeting IL-1 Signalling for the Treatment of Breast Cancer Bone Metastasis. Cancers, 14(19), 4816-4816.
• Hughes R, Chen X, Cowley N, Ottewell PD, Hawkins RJ, Hunter KD, Hobbs JK, Brown NJ & Holen I () Osteoblast-Derived Paracrine and Juxtacrine Signals Protect Disseminated Breast Cancer Cells from Stress. Cancers, 13(6), 1366-1366.
• Al-Sahaf S, Hendawi NB, Ollington B, Bolt R, Ottewell PD, Hunter KD & Murdoch C () Increased Abundance of Tumour-Associated Neutrophils in HPV-Negative Compared to HPV-Positive Oropharyngeal Squamous Cell Carcinoma Is Mediated by IL-1R Signalling. Frontiers in Oral Health, 2.
• Clezardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F, Confavreux CB & Holen I () Bone Metastasis: Mechanisms, Therapies and Biomarkers. Physiological Reviews.
• Ran R, Harrison H, Ariffin NS, Ayub R, Pegg HJ, Deng W, Mastro A, Ottewell PD, Fowles AM, Blyth SMMK , Holen I et al () RUNX/CBFβ transcription factor complexes promote the phenotypic plasticity of metastatic breast cancer cells.
• Haider M-T, Ottewell PD, Brown NJ, Lefley DV & Holen I () Peripheral tumour re-growth following combination therapy - role of the bone microenvironment. Bone Abstracts.
• Bradbury S, Rennicks S, Evans A, del CBM, Holen I & Ottewell P () Blocking IL-1R signalling inhibits breast cancer growth and bone metastases by altering the tumour microenvironment. Bone Abstracts.
• Ottewell PD () 11th International Conference on Cancer-Induced Bone Disease. IBMS BoneKEy, 9.
• Kwan A, Winder NJ, Atkinson E, Al-Janabi HH, Allen RJ, Hughes R, Moamin MR, Louie R, Evans D, Hutchinson M , Capper DT et al () Macrophages Mediate the Anti-Tumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors. Molecular Cancer Therapeutics, molcanther.0748.2020-molcanther.0748.2020.
• Quayle LA, Spicer A, Ottewell PD & Holen I () Transcriptomic Profiling Reveals Novel Candidate Genes and Signalling Programs in Breast Cancer Quiescence and Dormancy. Cancers, 13(16), 3922-3922.

Chapters

• Holen I, Saleh L, Ottewell PD & Lawson MA (2022) In vivo models used in studies of bone metastases, Bone Cancer (pp. 35-53). Elsevier
• George C, Michael N & Ottewell PD (2022) Bone, a fertile soil for tumor development, Bone Cancer (pp. 121-128). Elsevier
• Ottewell PD & Quayle LA (2019) Tumor Dormancy in the Bone In Caplan M (Ed.), Reference Module in Biomedical Sciences Elsevier View this article in WRRO
• Tulotta C, Groenewoud A, Snaar-Jagalska BE & Ottewell P (2019) Animal Models of Breast Cancer Bone Metastasis, Methods in Molecular Biology (pp. 309-330). Springer New York

Conference proceedings papers

• Saleh L, Ottewell PD, Brown JE, Wood SL, Brown NJ, Wilson C, Park C & Holen I (2020) Preventing the progression of breast cancer bone metastasis by CDK inhibition. BREAST CANCER RESEARCH AND TREATMENT, Vol. 180(2) (pp 537-538)
• Tulotta C, Moore CK, Lefley DV, Amariutei AE, Ahmed K, Spicer-Hadlington AR & Ottewell PD (2020) Inhibition of breast cancer bone metastasis through Interleukin-1B regulated tumour-associated innate immune response. BREAST CANCER RESEARCH AND TREATMENT, Vol. 180(2) (pp 538-539)
• Moamin MR, Monk P, Cox A, Ottewell P, Saint-Pol J, Rubinstein E & Muthana M (2019) Abstract LB-036: Tetraspanin 5 expressing macrophages promote mammary tumor growth. Tumor Biology
• Moamin MR, Monk P, Cox A, Ottewell P, Saint-Pol J, Rubinstein E & Muthana M (2019) Abstract LB-036: Tetraspanin 5 expressing macrophages promote mammary tumor growth. Tumor Biology
• Ottewell PD, Lefley DV, Freeman K, Gregory WM, Hanby AM, Spicer-Hadlington AR, Liu X, Bradbury SM, Hambley L, Allocca G , Cookson V et al (2019) Abstract P1-05-01: Breast cancer cell-derived IL-1B drives metastasis and colonisation of the bone microenvironment. Poster Session Abstracts
• Hughes R, Ottewell P, Hobbs J, Holen I & Brown NJ (2019) Breast Cancer Metastasis to Bone: The Role of the Perivascular Niche in Regulating Tumour Cell Dormancy. JOURNAL OF VASCULAR RESEARCH, Vol. 56 (pp 17-18)
• (2018) 1st UK Interdisciplinary Breast Cancer Symposium—15th–16th January 2018. Breast Cancer Research and Treatment, Vol. 167(1) (pp 309-405)
• Eyre R, Alferez D, Santiago-Gomez A, Spence K, McConnell J, Simoes B, Hart C, Lefley D, Tulotta C, Gurney A , Howell S et al (2017) Targeting IL-1 beta-Wnt signalling to prevent breast cancer colonisation in the bone microenvironment. CLINICAL & EXPERIMENTAL METASTASIS, Vol. 34(8) (pp 493-493)
• Tulotta C, Lefley D, Liu X, Spicer-Hadlington A, Hamley L, Cookson V, Allocca G & Ottewell P (2017) IL-1B signalling regulates breast cancer bone metastasis. CLINICAL & EXPERIMENTAL METASTASIS, Vol. 34(8) (pp 516-516)
• Lefley D, Nutter F, Brown H, Tulotta C, Eyre R, Clarke R, Alferez D, Wilkinson M, Holen I & Ottewell P (2017) Human specific models for studying ER plus ve and ER- ve breast cancer bone metastasis. CLINICAL & EXPERIMENTAL METASTASIS, Vol. 34(8) (pp 516-516) View this article in WRRO
• Quayle L, Park S, McDonnell DP, Ottewell PD & Holen I (2017) Abstract P3-07-14: Targeting ERR-α regulated lactate metabolism eliminates drug-resistant breast cancer cells. Poster Session Abstracts
• Ottewell P, Brown H, Allocca G, Haider MT, Brown N & Holen I (2016) The bone microenvironment as a master regulator of tumour cell dormancy in breast cancer - evidence from novel in vivo models. EUROPEAN JOURNAL OF CANCER, Vol. 61 (pp S74-S75)
• Byrne M, Ottewell PD, Holen I, Sanderson T & Cross SS (2012) The Use of p63 in Distinguishing In Situ and Invasive Tumour in the PyMT Mouse Model of Breast Cancer. JOURNAL OF PATHOLOGY, Vol. 228 (pp S38-S38)
• Brown HK, Ottewell PD, Evans CA, Coleman RE & Holen I (2011) Early intervention with a single dose of doxorubicin followed by zoledronic acid induces sustained inhibition of breast cancer-induced bone disease in a mouse model. BONE, Vol. 48 (pp S255-S255)
• Ottewell PD, Whitworth J & Holen I (2011) THE ROLE OF PLAKOGLOBIN IN THE INITIATION OF BREAST CANCER METASTASES. ANNALS OF ONCOLOGY, Vol. 22 (pp 32-32)
• Ottewell PD, Brown H, Rogers TL, Lefley DV, Evans AC, Wind N, Cross SS, Brown N, Coleman R & Holen I (2011) PREVENTION OF SPONTANEOUS MAMMARY TUMOUR GROWTH BY SEQUENTIAL ADMINISTRATION OF DOXORUBICIN AND ZOLEDRONIC ACID IN AN IMMUNOCOMPETENT MOUSE MODEL. ANNALS OF ONCOLOGY, Vol. 22 (pp 29-29)
• Ottewell PD, Whitworth J & Holen I (2011) THE ROLE OF PLAKOGLOBIN IN THE INITIATION OF BREAST CANCER METASTASES. ANNALS OF ONCOLOGY, Vol. 22 (pp 32-32)
• Ottewell PD, Brown H, Rogers TL, Lefley DV, Evans AC, Wind N, Cross SS, Brown N, Coleman R & Holen I (2011) PREVENTION OF SPONTANEOUS MAMMARY TUMOUR GROWTH BY SEQUENTIAL ADMINISTRATION OF DOXORUBICIN AND ZOLEDRONIC ACID IN AN IMMUNOCOMPETENT MOUSE MODEL. ANNALS OF ONCOLOGY, Vol. 22 (pp 29-29)
• Wind NS, Brown H, Ottewell PD, Sadej R, Romanska H, Berditchevski F & Holen I (2011) Does differential expression of CD151 affect the ability of beast cancer cells to establish tumours in bone?. BONE, Vol. 48(1) (pp S45-S45)
• Brown HK, Ottewell PD, Evans CA, Coleman RE & Nolen I (2011) Combination vs single agent treatment: The effects of zoledronic acid +/- doxorubicin on breast tumour growth in bone prior to development of osteolytic bone disease. BONE, Vol. 48(1) (pp S41-S41)
• Ottewell PD, Brown H, Evans CA, Wind NS, Brown NJ, Coleman RE & Holen I (2011) First evidence for anti-tumour effects of doxorubicin and zoledronic acid from an immunocompetent mouse model. BONE, Vol. 48(1) (pp S42-S42)
• Westbrook JA, Peng J, Cairns DA, Ottewell PD, Holen I, Coleman RE, Selby PJ, Banks RE & Brown JE (2011) Towards biomarkers of bone-metastasis using cellular proteomics. BONE, Vol. 48(1) (pp S33-S33)
• Brown HK, Ottewell PD, Evans CA & Holen I (2011) Changes in osteoblast and osteoclast number rely on direct contact with breast cancer cells - Evidence from a longitudinal study of bone metastasis. BONE, Vol. 48(1) (pp S40-S41)
• Holen I, Ottewell PD & Coleman RE (2010) Abstract P6-14-03: Zoledronic Acid Reduces Breast Tumour Growth When Combined with Chemotherapy — Emerging Evidence of Anti-Tumour Effects Outside Bone. Poster Session Abstracts
• Ottewell PD, Lefely DV, Cross SS, Coleman RE & Holen I (2010) Sustained inhibition of tumour growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid. BONE, Vol. 47 (pp S317-S317)
• Brown HK, Ottewell PD, Lefely DV, Coleman RE & Holen I (2010) Effects of doxorubicin followed by zoledronic acid on early, medium and late stage breast tumour growth in bone. BONE, Vol. 47 (pp S318-S319)
• Woodward J, Holen I, Lefley D, Ottewell P & Buttle D (2010) Breast cancer-bone marrow stromal cell interactions modify expression of proteolytic enzymes and regulators of bone turnover. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Vol. 91(2) (pp A45-A46)
• Ottewell PD, Leftey DV, Coleman RE & Holen I (2009) Evaluation of the molecular mechanisms for the sequence-dependent, synergistic anti-tumour effects of doxorubicin and zoledronic acid in breast cancer.. CANCER RESEARCH, Vol. 69(2) (pp 200S-201S)
• Ottewell P, Coleman RE & Holen I (2008) Mechanisms of apoptosis and cell cycle arrest in sub-cutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid. European Journal of Cancer Supplements, Vol. 6(9) (pp 18-18)
• Ottewell PD, Lefley DV, Coleman RE & Holen I (2008) Mechanisms of apoptosis and cell-cycle arrest in subcutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid. BREAST CANCER RESEARCH, Vol. 10 (pp S40-S41) View this article in WRRO
• Lefley DV, Holen I, Coleman RE & Ottewell PD (2008) Pretreatment of breast cancer cells with doxorubicin facilitates the subsequent uptake of zoledronic acid. BREAST CANCER RESEARCH, Vol. 10 (pp S40-S40) View this article in WRRO
• Ottewell P, Croucher P & Holen I (2008) P1. Breast cancer cells cause a reduction in osteoblast number – An early event in the development of osteolytic bone lesions. Cancer Treatment Reviews, Vol. 34 (pp 12-12)
• Ottewell P, Coleman R & Holen I (2008) P18. Mechanisms of apoptosis and cell cycle arrest in intra-tibial breast tumours treated sequentially with doxorubicin followed by zoledronic acid. Cancer Treatment Reviews, Vol. 34 (pp 19-19)
• Woodward J, Lefley D, Cross N, Ottewell PD, Buttle DJ, Coleman RE & Holen I (2007) Tumour cell-bone marrow stromal cell interactions modify expression of cathepsin K, ADAMTS-15, TIMP-3 and osteoprotegerin (OPG). INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Vol. 88(6) (pp A97-A97)
• Ottewell PD, Deux B, Monkkonen H, Cross SS, Coleman RE, Clezardin P & Holen I (2007) Differential effects of doxorubicin and zoledronic acid on intra-osseous vs extra-osseous breast tumour growth in vivo.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 106 (pp S39-S39)
• Ottewell PD, Deux B, Monkkonen H, Coleman RE, Clezardin P & Holen I (2007) Differential effect of doxorubicin and zoledronic acid on intra-osseous vs extra osseous breast tumour growth in vivo. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1111-1111)
• Woodward JKL, Lefley DV, Cross NA, Ottewell PD, Battle DJ, Coleman RE & Holen I (2007) Tumour cell-bone marrow stromal cell interactions modify expression of cathepsin K, ADAMTS-15, TIMP-3 and osteoprotegerin (OPG). JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1142-1143)
• Van Pozanki C, Otterwell P, Cross S, Hudis C, Coleman RE & Holen I (2007) Osteoprotegerin (OPG) expression in breast tumors and bone metastases. INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, Vol. 22(1) (pp 83-84)
• Cross SS, Ottewell P, Swinscoe M, Majeed AW & Holen I (2006) Osteoprotegerin is strongly expressed in the intratumoural endothelial cells of gastrointestinal carcinomas. JOURNAL OF PATHOLOGY, Vol. 208 (pp 9A-9A)
• Van Poznak C, Ottewell P, Cross S, Hudis C, Coleman RE & Holen I (2006) Osteoprotegerin (OPG) expression in breast tumours and bone metastases. Bone, Vol. 38(3) (pp 31-32)
• Ottewell PD, Jones M, Coleman RE & Holen I (2006) Synergistic effects of zoledronic acid and doxorubicin in breast cancer models in vivo. CANCER TREATMENT REVIEWS, Vol. 32 (pp S30-S30)
• Ottewell PD, Jones M, Coleman RE & Holen I (2006) Synergistic effects of cytotoxic drugs and antiresorptive agents in vitro and in vivo. BREAST CANCER RESEARCH, Vol. 8 (pp S17-S17) View this article in WRRO
• Ottewell PD, Jones M, Coleman RE & Holen I (2006) Synergistic effects of cytotoxic drugs and anti-resorptive agents in vitro and in vivo.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 100 (pp S290-S290)
• Duckworth CA, Ottewell PD, Dimaline R, Varro A & Pritchard DM (2005) Hypergastrinaemia reduces the severity of dextran sulphate sodium induced colitis and 5-fluorouracil induced mucositis in mice. GUT, Vol. 54 (pp A98-A98)
• Duckworth CA, Ottewell PD, Varro A, Dimaline R & Pritchard DM (2005) Hypergastrinaemia reduces the severity of dextran sulphate sodium induced colitis and 5-fluorouracil induced intestinal mucositis in mice.. GASTROENTEROLOGY, Vol. 128(4) (pp A203-A203)
• Ottewell PD, Watson AJ, Varro A & Pritchard DM (2005) Radiation induces gastrin-CCKB receptor expression in IEC-6 and IEC-18 intestinal epithelial cells. GUT, Vol. 54 (pp A88-A88)
• Przemeck SMC, Ottewell PD, Watson AJM & Pritchard DM (2005) Radiation induces p53 dependent apoptosis in the proliferative zone of mouse gastric epithelium. GUT, Vol. 54 (pp A88-A88)
• Davies A, Ottewell P, McNamara A, Jenkins JR & Watson AJM (2004) Etoposide induced p53-dependent gene expression in the GI tract: Analysis of BIRC3, a candidate gene. GASTROENTEROLOGY, Vol. 126(4) (pp A546-A546)
• Ottewell PD, Varro A, Watson AJM, Dimaline R, Dockray GJ & Pritchard DM (2004) Progastrin stimulates murine colonic epithelial mitosis after DNA damage in the absence of murine amidated gastrin. GASTROENTEROLOGY, Vol. 126(4) (pp A272-A272)
• Ottewell PD, Watson A, Wang T, Dockray G & Pritchard M (2003) Progastrin stimulates murine colonic mitosis after DNA damage via the cyclin D1-cdk4 complex. GASTROENTEROLOGY, Vol. 124(4) (pp A100-A100)
• Ottewell PD, Watson A, Wang T, Varro A, Dockray G & Pritchard M (2003) Elevated plasma concentrations of amidated gastrin cause increased crypt survival in murine intestinal epithelia after Gamma-radiation. GASTROENTEROLOGY, Vol. 124(4) (pp A610-A610)
• Ottewell PD, Watson AJM, Wang TC, Varro A, Dockray GJ & Pritchard DM (2003) Elevated plasma concentrations of amidated gastrin cause increased crypt survival in murine intestinal epithelia after gamma radiation. GUT, Vol. 52 (pp A8-A8)
• Davies A, Ottewell PD, McNamara A, Watson AJM & Jenkins JR (2003) P53 dependent differential expression analysis of etoposide induced stress in the murine small intestine. GUT, Vol. 52 (pp A36-A36)
• Ottewell PD, Watson AJM, Wang TC, Dockray GJ & Pritchard DM (2003) Progastrin stimulates murine colonic mitosis after DNA damage via the cyclin D-cdk4 complex. GUT, Vol. 52 (pp A55-A55)
• McMichael DP, Davies A, Marshman E, Ottewell PD, Jenkins JR & Watson AJM (2001) Knockout mouse and gene array analysis of etoposide induced apoptosis in the murine small intestine. GUT, Vol. 48 (pp A61-A62)
• Arshad F, Lefley D, Madan S, Fernandes J, Bishop N & Ottewell P () Developing a human-mouse hybrid model of osteogenesis imperfecta for investigating new therapies for children. Bone Abstracts
• Bishop N, Kalajzic I, Arshad F, Lefley D, Gossiel F & Ottewell P () Losartan reduces circulating TGFb and CTX and increases vertebral bone mass in the OIM mouse. Bone Abstracts

Preprints

• Shah KM, Tattersall L, Hussain A, Macfarlane SC, Williamson A, Acosta-Martin AE, Erler JT, Ottewell PD & Gartland A () P2RX7 inhibition reduces breast cancer induced osteolytic lesions - implications for bone metastasis, Cold Spring Harbor Laboratory.